2015 Annual General and Special Meeting of Shareholders

Meeting Agenda

Critical Outcome Technologies Inc.

- MEETING CALLED TO ORDER – Mr. John Drake, Chairman of the Board
- CHAIR'S OPENING REMARKS
- APPOINTMENT OF THE SECRETARY FOR THE MEETING
- APPOINTMENT OF THE SCRUTINEER & SCRUTINEER'S REPORT
- READING OF THE NOTICE OF THE MEETING
- READING OF THE MINUTES OF THE ANNUAL MEETING OF SHAREHOLDERS OF OCTOBER 21, 2014
- FINANCIAL STATEMENTS
- FIX THE NUMBER OF DIRECTORS
- ELECTION OF THE DIRECTORS
- APPOINTMENT OF THE AUDITOR AND FIX THEIR REMUNERATION
- CONTINUATION OF THE COMPANY'S STOCK OPTION PLAN AS A ROLLING PLAN
- THE BUSINESS AND SCIENTIFIC UPDATE PRESENTATION – Dr. W Danter, CEO
- OTHER BUSINESS


Critical Outcome
Technologies Inc.
Business and Scientific Update

Disclaimer

When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).

COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI's public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.

All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.

2015 Strategic Goals

Critical Outcome Technologies Inc.

1. Obtain Investigational New Drug (IND) Status for COTI-2 from the US FDA
2. Increase value of COTI-2 by identifying new clinical trial indications and combination therapies
3. Appoint Scientific Advisory Board for the clinical development of COTI-2 & other pipeline assets
4. Commence Phase 1 clinical trial for COTI-2 in patients with advanced gynecologic cancers
5. Select our next clinical candidate for development

#1: IND Status for COTI-2

Critical Outcome Technologies Inc.

April 2015

Filed our IND application

May 2015

IND status granted by U.S. Food and Drug Administration for COTI-2 in gynecologic cancers

#2: Identify New Indications/Comb. Therapies

Critical Outcome Technologies Inc.

- Exploring clinical trials for other indications:
  - Head and neck (orphan) 2016
  - Li-Fraumeni syndrome (orphan) 2016
  - AML (orphan)
  - NSCLC

- COTI-2 effective when combined with many first line therapies:
  - Chemotherapy
  - Immunotherapy – actively developing research collaborations

#3: Establish Scientific Advisory Board

Critical Outcome Technologies Inc.

March 2015

Established high-profile Scientific Advisory Board for the clinical development of COTI-2 and other pipeline assets

Chaired by Dr. Gordon Mills

#4: Commence Phase 1 for COTI-2

Critical Outcome Technologies Inc.

- Expected to commence October 2015 at MDACC
- Up to 46 women with gynecological cancers
  - Enriched with ovarian cancer patients
  - No chemo/radiation for at least 28 days prior to starting
  - Follow for up to 6 months of treatment
- Expected to take 18 months to complete
  - Interim data at ~ 9 months into the study

#5: Select Next Candidate for Development

Critical Outcome Technologies Inc.

Options are:

1. COTI-219, a unique oncology drug candidate for CRC and other cancers with RAS mutations
2. COTI-AML-01, a multi-kinase inhibitor for Acute Myelogenous Leukemia (AML)
3. COTI-HIV-II, second generation dual HIV Integrase inhibitor
4. COTI-MRSA1, highly novel antibiotic program

All potential candidates discovered by our CHEMSAS® platform

CHEMSAS: Our Pipeline

Critical Outcome Technologies Inc.

Compound	Target	CHEMSAS®	Lead Selection	Synthesis	Preclinical	Phase 1
COTI-2 (p53)						
AML						
Colon						
COTI-219						
COTI-4						
COTI-58						
Other Programs*						



***Programs for MRSA, Multiple sclerosis, Alzheimer's, and HIV Integrase**

Critical Outcome Technologies Inc.

COTI-2

A potential breakthrough therapy for many cancers

P53-dependent mechanism of action

Critical Outcome Technologies Inc.

- Demonstrated selective and potent anti-cancer activity in pre-clinical experiments
- Effective against many common cancers with a p53 gene mutation
- > 50% of all human cancers have a p53 mutation
  (e.g. ~ 95% of serous ovarian cancers)

"a promising advance" for many cancers with p53 mutations." – Dr. G.B. Mills, MDACC



COTI-2: Impressive single agent activity

Critical Outcome Technologies Inc.



Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control

Orphan Drug Designation

Critical Outcome Technologies Inc.

- Granted by the FDA for the treatment of ovarian cancer – June 2014
- Potentially qualifies us for:
  - Assistance in clinical trial design
  - Expedited drug development – Fast track designation
  - Development grants & fee reductions
  - 7-year exclusive marketing period

Other COTI-2 Highlights

Critical Outcome Technologies Inc.

- Orally bio-available and effective at low dose
- Low toxicity in preclinical development
- Opportunity for both single agent and combination therapy
- Strong US and international IP protection in place

Out-license vs Phase 2

Critical Outcome Technologies Inc.

Positive Phase 1 results will create important options:

- Out-license
  - Validates scientific platform and commercial strategy
  - May not realize maximum shareholder/asset value
- Phase 2
  - Moon shot project at MDACC possible
  - Maximizes asset value

Shareholder value creation 2015

Critical Outcome Technologies Inc.

COTI share price performance compared with TSX.V



Strategic goals for 2016

Critical Outcome Technologies Inc.

2016 Strategic Goals

Critical Outcome Technologies Inc.

1. Guide COTI-2 to successful completion of first Phase 1 human trial and licensing deal
2. Identify and commence at least one additional Phase 1 clinical trial in 2016
3. Identify our next clinical candidate and drive it towards the clinic
4. Plan for strategic growth in the US
   - Boston based office
   - Uplift to NASDAQ listing

Thank you





Critical Outcome Technologies Inc.

2015 Annual General and Special Meeting of Shareholders